SRX Global to acquire CERo Therapeutics unit in $1M stock deal, forgiving $8.25M note

SRx Health Solutions, Inc.

SRX will issue Holdings $1,000,000 of common stock, priced at the lower of the pre-signing close or 20-day VWAP on the NYSE American, and forgive the Consolidated Note.
Debt relief covers the note's up to $11,666,108.77 original principal ($8,249,643.77 outstanding) plus interest; SRX assumes ~$1,562,000 of liabilities.
A 30-day go-shop lets Holdings solicit rival bids via Joseph Gunnar & Co.; a Superior Proposal must close by March 15, 2027 and repay the Secured Note.
Holdings owes a $750,000 termination fee; SRX owes Holdings $750,000 if it fails to fund; Buyer expense reimbursement is capped at $100,000.
Closing requires Series A preferred consents/conversion plus acquisition of Holdings' Series C, D and E preferred; 180-day lock-ups and key-employee pacts are contemplated.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.